Diamantopoulos, Panagiotis T.
Charakopoulos, Emmanouil
Symeonidis, Argiris
Kotsianidis, Ioannis
Viniou, Nora-Athina
Pappa, Vassiliki
Pontikoglou, Charalampos
Tsokanas, Dimitrios
Drakos, Georgios
Kourakli, Alexandra
Solomou, Elena
Hatzimichael, Eleftheria
Pouli, Anastasia
Kotsopoulou, Maria
Asmanis, Evangelos
Dimou, Maria
Panayiotidis, Panayiotis
Papageorgiou, Sotirios
Vassilopoulos, Georgios
Anagnostopoulos, Achilles
Vassilakopoulos, Theodoros
Papadaki, Helen
Galanopoulos, Athanasios
Funding for this research was provided by:
Novartis (011/ 21-11-2014)
Article History
Received: 29 January 2022
Accepted: 6 October 2022
First Online: 26 October 2022
Competing interests
: Panagiotis T. Diamantopoulos reports personal fees for presentations for Celgene, Janssen, and Novartis. Argiris Symeonidis and Nora-Athina Viniou report investigational grants and personal fees for presentations and advisory roles from Celgene/Genesis Pharma, Novartis, and Roche. Ioannis Kotsianidis, Vassiliki Pappa, Athanasios Galanopoulos, and Panayiotis Panayiotidis report personal fees for honoraria and advisory roles from Celgene/Genesis Pharma. Maria Dimou reports personal fees for advisory roles from Celgene/Genesis Pharma. The remaining authors declare that they have no conflict of interest.